Blue Barn Wealth LLC Has $293,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Blue Barn Wealth LLC increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 12.9% in the fourth quarter, HoldingsChannel reports. The firm owned 1,801 shares of the company’s stock after purchasing an additional 206 shares during the period. Blue Barn Wealth LLC’s holdings in Zoetis were worth $293,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Howard Capital Management Group LLC lifted its holdings in Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after acquiring an additional 883 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Zoetis by 3.2% in the 3rd quarter. Janney Montgomery Scott LLC now owns 103,884 shares of the company’s stock valued at $20,297,000 after purchasing an additional 3,208 shares during the period. FSM Wealth Advisors LLC bought a new position in shares of Zoetis during the 3rd quarter worth approximately $243,000. Avidian Wealth Enterprises LLC grew its stake in Zoetis by 5.0% in the 3rd quarter. Avidian Wealth Enterprises LLC now owns 2,322 shares of the company’s stock valued at $454,000 after buying an additional 111 shares during the last quarter. Finally, Callahan Advisors LLC boosted its stake in Zoetis by 4.7% in the 3rd quarter. Callahan Advisors LLC now owns 6,884 shares of the company’s stock valued at $1,345,000 after purchasing an additional 306 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Down 1.7 %

NYSE ZTS opened at $166.96 on Thursday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The firm has a market capitalization of $74.76 billion, a PE ratio of 30.52, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The stock’s 50 day moving average is $166.57 and its 200 day moving average is $176.99.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.20%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is currently 36.56%.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.16% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Morgan Stanley lowered their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. StockNews.com downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday, February 25th. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Barclays increased their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.